Prostate cancer and prostatic diseases · 2026
MUSegNet: Automated detection of clinically significant prostate cancer on micro-ultrasound.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rusu Mirabela, Zhou Steve R, Zhang Lichun, Choi Moon Hyung, Vesal Sulaiman, Kinnaird Adam S, Brisbane Wayne G, Lughezzani Giovanni, Maffei Davide, Fasulo Vittorio, Albers Patrick, El-Kaffas Ahmed, Shao Wei, Fan Richard E, Sonn Geoffrey A
Аннотация
BACKGROUND: Micro-ultrasound (microUS) is a non-inferior alternative to multi-parametric MRI for clinically significant prostate cancer (csPCa) diagnosis, yet cancer's subtle features result in missed cancers and large inter-reader variability. We seek to automate the detection of csPCa on microUS by developing the microUS Prostate Cancer Detection Network (MUSegNet).
METHODS: Implemented using the well-established segmentation framework, nnUnet, MUSegNet automatically outlines the prostate, transitional zone, and csPCa. Our study explored strategies to train such segmentation models given reduced data, which is common with new imaging modalities such as microUS and/or when labeling data is tedious. MUSegNet was trained using three datasets: (1) 53 microUS exams manually labeled using MRI and pathology references (53 patients), (2) 565 unlabeled microUS exams (106 patients), and (3) 2749 conventional b-mode ultrasound exams (2281 patients). We evaluated MUSegNet in 73 independent patients from two institutions, against manual labels and in direct comparison with six expert readers.
RESULTS: MUSegNet was significantly better at detecting csPCa than the baseline models trained using manual labels (area under the receiver operating characteristic curve - AUROC; 0.85 vs. 0.73, Delong p-value < 0.01, sensitivity: 0.74 vs. 0.27, dice similarity coefficient: 0.29 vs. 0.09, Wilcoxon p-value < 0.001). MUSegNet was better at detecting posterior vs. anterior lesions (AUROC: 0.94 vs. 0.72, sensitivity: 0.86 vs. 0.49, Dice: 0.31 vs. 0.11) and outperformed the six human readers for all lesions (AUROC: 0.85 vs. 0.78, sensitivity: 0.74 vs. 0.63). While evaluation in a larger cohort is needed, MUSegNet found csPCA in 33% of cases with csPCa and MRI invisible cancers (1 in 3).
CONCLUSIONS: MUSegNet reliably detected the extent of clinically significant prostate cancer on micro-ultrasound exams, paving the way for improving cancer detection for biopsy targeting and reducing inter-reader variability. MUSegNet was best at capturing posterior cancers, with some benefit for the challenging anterior cancers.
METHODS: Implemented using the well-established segmentation framework, nnUnet, MUSegNet automatically outlines the prostate, transitional zone, and csPCa. Our study explored strategies to train such segmentation models given reduced data, which is common with new imaging modalities such as microUS and/or when labeling data is tedious. MUSegNet was trained using three datasets: (1) 53 microUS exams manually labeled using MRI and pathology references (53 patients), (2) 565 unlabeled microUS exams (106 patients), and (3) 2749 conventional b-mode ultrasound exams (2281 patients). We evaluated MUSegNet in 73 independent patients from two institutions, against manual labels and in direct comparison with six expert readers.
RESULTS: MUSegNet was significantly better at detecting csPCa than the baseline models trained using manual labels (area under the receiver operating characteristic curve - AUROC; 0.85 vs. 0.73, Delong p-value < 0.01, sensitivity: 0.74 vs. 0.27, dice similarity coefficient: 0.29 vs. 0.09, Wilcoxon p-value < 0.001). MUSegNet was better at detecting posterior vs. anterior lesions (AUROC: 0.94 vs. 0.72, sensitivity: 0.86 vs. 0.49, Dice: 0.31 vs. 0.11) and outperformed the six human readers for all lesions (AUROC: 0.85 vs. 0.78, sensitivity: 0.74 vs. 0.63). While evaluation in a larger cohort is needed, MUSegNet found csPCA in 33% of cases with csPCa and MRI invisible cancers (1 in 3).
CONCLUSIONS: MUSegNet reliably detected the extent of clinically significant prostate cancer on micro-ultrasound exams, paving the way for improving cancer detection for biopsy targeting and reducing inter-reader variability. MUSegNet was best at capturing posterior cancers, with some benefit for the challenging anterior cancers.